0. Abstract
Introduction Model projections of COVID-19 incidence into the future help policy makers about decisions to implement or lift control measures. During 2020, policy makers in the Netherlands were informed on a weekly basis with short-term projections of COVID-19 intensive care unit (ICU) admissions. Here we present the model and the procedure by which it was updated.
Methods the projections were produced using an age-structured transmission model. A consistent, incremental update procedure that integrated all new surveillance and hospital data was conducted weekly. First, up-to-date estimates for most parameter values were obtained through re-analysis of all data sources. Then, estimates were made for changes in the age-specific contact rates in response to policy changes. Finally, a piecewise constant transmission rate was estimated by fitting the model to reported daily ICU admissions, with a change point analysis guided by Akaike’s Information Criterion.
Results The model and update procedure allowed us to make mostly accurate weekly projections, accounting for recent and future policy changes, and to adapt the estimated effectiveness of the policy changes based only on the natural accumulation of incoming data.
Discussion The model incorporates basic epidemiological principles and most model parameters were estimated per data source. Therefore, it had potential to be adapted to a more complex epidemiological situation, as it would develop after 2020.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Collection of the PiCo serological data was approved by the Medical Ethics Committee MEC-U, the Netherlands (Clinical Trial Registration NTR8473). For collection of the OSIRIS and NICE surveillance data, the Centre for Clinical Expertise at the RIVM verified that it does not fulfill the specific conditions stated in article 1 of the Dutch law for Medical Research Involving Human Subjects (WMO), and that approval by an ethical research committee was therefore unnecessary (RIVM study number EPI-623).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Some symbols in equations were corrupted when making the pdf, which I had not noticed; now everything looks good.
Data and code availability
Most data contain person-disclosing information and cannot be shared. To reproduce all analyses of the last week of this study (6 January 2021), all code is made available with synthetic data to run the data analyses resulting in approximately the same parameter estimates, and with original parameter estimates to reproduce the exact simulation results. Code and synthetic data can be found at www.github.com/rivm-syso/COVID-projectionmodel.
